Evaluate Immunogenicity and Safety of a Single or Double-Dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-Administration Schedule (21 Days Apart) in Adults Over 60 Yrs.

Trial Profile

Evaluate Immunogenicity and Safety of a Single or Double-Dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-Administration Schedule (21 Days Apart) in Adults Over 60 Yrs.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; AS03A
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Apr 2011 Results published in the Journal of Infectious Diseases.
    • 13 Oct 2009 Actual patient number changed from 437 to 320 as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top